Head-To-Head Review: BioTelemetry (BEAT) vs. Acadia Healthcare (ACHC)

BioTelemetry (NASDAQ: BEAT) and Acadia Healthcare (NASDAQ:ACHC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

How to Become a New Pot Stock Millionaire

This table compares BioTelemetry and Acadia Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioTelemetry -5.56% 14.54% 8.08%
Acadia Healthcare 6.92% 8.16% 3.15%

Earnings & Valuation

This table compares BioTelemetry and Acadia Healthcare’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioTelemetry $286.78 million 3.49 -$15.95 million $0.97 31.55
Acadia Healthcare $2.84 billion 1.23 $199.83 million $2.30 17.16

Acadia Healthcare has higher revenue and earnings than BioTelemetry. Acadia Healthcare is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioTelemetry and Acadia Healthcare, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioTelemetry 1 0 6 0 2.71
Acadia Healthcare 0 5 10 0 2.67

BioTelemetry currently has a consensus target price of $43.67, indicating a potential upside of 42.70%. Acadia Healthcare has a consensus target price of $43.31, indicating a potential upside of 9.75%. Given BioTelemetry’s stronger consensus rating and higher possible upside, equities research analysts plainly believe BioTelemetry is more favorable than Acadia Healthcare.

Institutional and Insider Ownership

87.6% of BioTelemetry shares are owned by institutional investors. 9.6% of BioTelemetry shares are owned by insiders. Comparatively, 11.1% of Acadia Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

BioTelemetry has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Acadia Healthcare has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Summary

BioTelemetry beats Acadia Healthcare on 8 of the 14 factors compared between the two stocks.

About BioTelemetry

BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

About Acadia Healthcare

Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities. The Company is engaged in operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As of December 31, 2016, the U.S. Facilities segment included 208 behavioral healthcare facilities with approximately 8,500 beds in 39 states and Puerto Rico, and the U.K. Facilities segment included 365 behavioral healthcare facilities with approximately 8,600 beds in the United Kingdom. As of December 31, 2016, the Company had operated 573 behavioral healthcare facilities with approximately 17,100 beds in 39 states, the United Kingdom and Puerto Rico.

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Diamond Offshore Drilling  – Research Analysts’ Weekly Ratings Updates
Diamond Offshore Drilling – Research Analysts’ Weekly Ratings Updates
Jabil  and Sparton  Head-To-Head Analysis
Jabil and Sparton Head-To-Head Analysis
Contrasting Netgear  & BlackBerry
Contrasting Netgear & BlackBerry
Critical Comparison: Nordstrom  and Its Competitors
Critical Comparison: Nordstrom and Its Competitors
NextEra Energy  Receives Average Rating of “Buy” from Analysts
NextEra Energy Receives Average Rating of “Buy” from Analysts
Kurrent  Trading Up 24.8% Over Last Week
Kurrent Trading Up 24.8% Over Last Week


© 2006-2018 Ticker Report. Google+.